Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Lund Hetland, Ulrik Tarp, Piet L C M van Riel, Dan C Nordström, Juan Gomez-Reino, Karel Pavelka, Matija Tomsic, Tore K Kvien, Ronald F van Vollenhoven, Cem Gabay

    64 Citationer (Scopus)

    Abstract

    OBJECTIVES: To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide.METHODS: 10 European registries submitted anonymised datasets with baseline, 3, 6, 9 and 12-month clinical data from patients who started rituximab.RESULTS: 1195 patients were treated with rituximab plus methotrexate, 177 with rituximab plus leflunomide and 505 with rituximab alone. Significantly more patients achieved a European League Against Rheumatism good response at 6 months when treated with rituximab plus leflunomide (29.1%) compared with rituximab plus methotrexate (21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, respectively). Similar results were observed at 12 months. Adverse events occurred in 10.2%, 13.2% and 13.9% of patients on rituximab plus leflunomide, rituximab plus methotrexate and rituximab alone, respectively.CONCLUSIONS: Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab. Slightly better results were obtained by the combination of rituximab and leflunomide than rituximab and methotrexate, raising the possibility of a synergistic effect of leflunomide and rituximab.
    OriginalsprogEngelsk
    TidsskriftAnnals of the Rheumatic Diseases
    Vol/bind71
    Udgave nummer3
    Sider (fra-til)374-377
    Antal sider4
    ISSN0003-4967
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration'. Sammen danner de et unikt fingeraftryk.

    Citationsformater